Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
Shifts to Value-Based Care and Payment Models Are Improving Quality of Care
By
Wayne Kuznar
Economics & Value
,
Reimbursement
,
Value-Based Care
August 2014, Vol 5, No 6
Blue Cross Blue Shield (BCBS) is implementing value-based care and payment models across the country to reward quality and improve outcomes, and these are amounting to billions of dollars in cost-savings and reduced hospitalizations.
Read Article
New Payment Models in Oncology Must Consider Value
Economics & Value
,
Reimbursement
August 2014, Vol 5, No 6
Economists predict that, in less than 3 years, the average household in the United States will use 50% of its income on health insurance and out-of-pocket medical bills. According to Lee N. Newcomer, MD, MHA, Senior Vice President, Oncology, Genetics and Women’s Health, UnitedHealthcare, Minnetonka, MN, creating payment models that can reimburse physicians for cost-effective care is difficult in itself, but demonstrating that the new models are indeed cost-effective involves another set of hurdles.
Read Article
ASCO Issues Recommendations on How to Fix the 340B Drug Pricing Program
By
Lilly Ostrovsky, MS
Economics & Value
,
Pricing
August 2014, Vol 5, No 6
In April, the American Society of Clinical Oncology (ASCO) released a policy statement recommending how to fix the 340B Drug Pricing Program.
Read Article
Telephone-Based Cancer Care Support Program Saves Big Bucks
By
Kate O'Rourke
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Telephone-based support programs are capable of reducing cancer-related medical costs by 10% to 30%, according to results of the first nurse-led study of the cost impact of telephonic case management in oncology.
Read Article
Secondary Oncology Pathways Can Have Big Cost Impact
By
Kate O'Rourke
Economics & Value
,
Economics of Cancer Care
,
Pathways
August 2014, Vol 5, No 6
Chicago, IL—The implementation of collaborative, secondary clinical pathway programs can improve outcomes and can lower costs when providers are already participating in another payer-sponsored pathway program. This conclusion comes from a study published online in conjunction with the 2014 American Society of Clinical Oncology meeting.
Read Article
Patients with Cancer Are Not Asking for Low-Value Tests or Therapies
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Contrary to common belief, there appears to be little demand on the part of patients with cancer for unsuitable, high-cost, low-value tests or therapies.
Read Article
Most Hospital Readmissions Not Preventable for Patients with Cancer
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Hospital readmissions in patients with cancer reflect the high burden of this disease, which is often refractory and, therefore, readmission is not reasonably preventable.
Read Article
Oncologists Want More Education on How to Discuss Cost of Treatment with Patients
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Oncologists responding to a national electronic survey believe that discussing out-of-pocket (OOP) costs of therapy with patients is important, and that OOP costs and societal cost of therapy will play a larger role in cancer treatment decisions over the next 5 years.
Read Article
Even When Adjusting for Improved Survival, Newer Anticancer Drugs Are More Expensive than Older Ones
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Even after adjusted for improved outcomes, newer anticancer drugs are more expensive than older agents, said Rena Conti, PhD, Assistant Professor of Health Policy and Economics, University of Chicago, at the 2014 American Society of Clinical Oncology meeting.
Read Article
Intravenous Cancer Treatments Pricier in Hospital than in Community Office Setting
By
Kate O'Rourke
2018 AONN+ Midyear Conference
,
Economics & Value
June 2014, Vol 5, No 5
Tampa, FL—Intravenous (IV) cancer therapies are more costly, by approximately 10%, when patients receive them in a hospital outpatient setting rather than in a community-based physician office, according to a study presented at the 2014 Academy of Managed Care Pharmacy meeting.
Read Article
Page 10 of 18
5
6
7
8
9
10
11
12
13
14
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma